tbuckley/cabot-search huggingface dataset:
Does pride really come before a fall? Longitudinal analysis of older English adults
Authors: D McMinn, S J Fergusson, M Daly
Journal: BMJ (2017)

<h3>Abstract</h3> <h3>Objective</h3> To test whether high levels of reported pride are associated with subsequent falls. <h3>Design</h3> Secondary analysis of the English Longitudinal Study of Ageing (ELSA) dataset. <h3>Setting</h3> Multi-wave longitudinal sample of non-institutionalised older English adults. <h3>Participants</h3> ELSA cohort of 6415 participants at wave 5 (baseline, 2010/11), of whom 4964 were available for follow-up at wave 7 (follow-up, 2014/15). <h3>Main outcome measures</h3> Self reported pride at baseline (low/moderate/high) and whether the participant had reported having fallen during the two years before follow-up. <h3>Results</h3> The findings did not support the contention that "pride comes before a fall." Unadjusted estimates indicate that the odds of reported falls were significantly lower for people with high pride levels compared with those who had low pride (odds ratio 0.69, 95% confidence interval 0.58 to 0.81, P&lt;0.001). This association remained after adjustment for age, sex, household wealth, and history of falls (odds ratio 0.81, 0.68 to 0.97, P&lt;0.05). It was partially attenuated after further adjustment for mobility problems, eyesight problems, the presence of a limiting long term illness, a diagnosis of arthritis or osteoporosis, medication use, cognitive function, and pain and depression (odds ratio 0.86, 0.72 to 1.03, P&lt;0.1). Because the confidence interval exceeded 1 in the final model, it remains possible that pride may not be an independent predictor of falls when known risk factors are considered. People with moderate pride did not have lower odds of having fallen than those with low pride in adjusted models. Participants lost to follow-up did not differ from those retained in terms of key variables, and weighting the analyses to account for selective attrition did not produce different results. <h3>Conclusions</h3> Contrary to the well known saying "pride comes before a fall," these findings suggest that pride may actually be a protective factor against falling in older adults. Future studies may seek to investigate the mechanisms underpinning this relation.
Antitumor effects of EGF-pathway immunization in NSCLC
Authors: J. Codony-Servat, S. García-Roman, M.A. Molina-Vila, J. Bertran-Alamillo, A. Giménez-Capitán, N. Karachaliou, E. D'Hondt, R. Rosell
Journal: Annals of Oncology (2017)
<i>The BMJ</i> charity appeal Christmas 2017: help MSF bring essential healthcare to millions of people in war torn Yemen
Authors: Richard Hurley
Journal: BMJ (2017)

Médecins Sans Frontières has decades of experience in bringing medical aid to the neediest people worldwide, such as the millions of civilians facing violence, cholera, and malnutrition in Yemen, as <b>Richard Hurley</b> writes. This is why <i>The BMJ</i> has chosen MSF for its charity appeal this year. Please give generously
High Frame-Rate Contrast Echocardiography: In-Human Demonstration
Authors: Matthieu E.G. Toulemonde, Richard Corbett, Virginie Papadopoulou, Navtej Chahal, Yuanwei Li, Chee Hau Leow, David O. Cosgrove, Robert J. Eckersley, Neill Duncan, Roxy Senior, Meng-Xing Tang
Journal: JACC. Cardiovascular imaging (2017)

In-Human Demonstration Contrast Echocardiography (CE) using microbubble contrast agents enables sensitive imaging of chamber flow dynamics and myocardial perfusion (1).However, the clinical value of CE is affected by the image quality achievable by the existing systems.Recent advances in ultrasound engineering, by transmitting nonfocused waves and digital beamforming, have made it possible to achieve thousands of frames per second (2) and offered new opportunities for imaging the dynamics of the heart.Although high frame-rate (HFR) echocardiography has recently been shown, challenges exist in noncontrast applications due to the difficulty of generating sufficient tissue harmonic signals in deep tissue using nonfocused waves, reducing image quality (3).In CE, such challenges disappear because the nonfocused waves can generate significant harmonics from microbubbles.HFR acquisition has the potential to enhance the imaging of both intraventricular flow and myocardial perfusion, although the mechanism of impacts is different.For imaging flow, HFR enables tracking of fast flow/vortex in the chamber.During perfusion imaging, in either triggered or continuous mode, HFR can acquire up to w100 frames within the same time as that required by the existing technique to acquire just a single frame.This can potentially reduce noise and minimize heart movement artifacts through temporal filtering or averaging a significant number of frames acquired within milliseconds.In this work we present, as far as we are aware, the first in human demonstration of HFR-CE.Contrast specific images at 5,500 frames/s were acquired on healthy human volunteers with infusion of Sonovue (Bracco Imaging SpA, Milan, Italy, 1.2 ml/min) (approved by the Imperial College Research Ethics Committee).Low mechanical index (0.08 to 0.12) diverging waves and pulse inversion sequences were transmitted using an ultrasound research platform (Verasonics, Kirkland, Washington) and a phased array probe (ATL P4-1, Phillips, Seattle, Washington).To improve the spatial resolution
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial
Authors: Moshe Mittelman, Uwe Platzbecker, Boris Afanasyev, Sebastian Grosicki, Raymond S M Wong, Achilles Anagnostopoulos, Benjamin Brenner, Claudio Denzlinger, Giuseppe Rossi, Arnon Nagler, Regina Garcia-Delgado, Maria Socorro O Portella, Zewen Zhu, Dominik Selleslag
Journal: The Lancet Haematology (2017)
Abstract 19446: Effect of Changing Sodium Intake on miRNA Profiling in Hypertensives
Authors: Haidong Zhu, Fenjun He, Jeong-Hyeon Choi, Yanbin Dong, Ying Huang, Gregory A Harshfield
Journal: Circulation (2016)

Introduction:  High sodium intake is an important risk factor for hypertension and CVD. However, the basic underlying mechanisms are not well understood. Animal studies demonstrate that miRNAs play a role in high sodium intake-induced myocardial fibrosis and salt-sensitive hypertension.   Hypothesis:  We aim to test the hypothesis that high sodium intake induced changes in circulating miRNA expression in hypertensives.   Methods:  A whole genome miRNA next generation sequencing was performed in paired serum samples (pre and post slow release sodium tablets) selected from 10 black male untreated hypertensive subjects (aged 43 to 68 years) in a randomized double-blind crossover trial (slow release sodium vs placebo while on low-sodium diet). Samples were sequenced on the Illumina NextSeq 500 system. The differential expression analysis was done using the EdgeR statistical software package. Benjamini-Hochberg FDR was used to adjust for multiple comparisons. mirTarBase (version 6.0) was used to identify miRNA target genes.   Results:  On average 10.2 million reads were obtained per sample. miR-425-3p (1.55 folds), miR-4433-3p (1.80 folds) and miR-4433-5p (1.54 folds) were significantly upregulated with an increase in sodium intake (raw  ps  0.80). miR-143-3p (0.71 folds), miR-223-5p (0.76 fold) and miR-148a-3p (0.82 folds) were significantly downregulated (raw  ps  0.80). miR-425-3p was involved in cell death. miR-143-3p was previously associated with apoptosis, and pulmonary arterial hypertension. miR-223-5p has been involved in obesity, sepsis-induced inflammation (IL6 and TNFα), myocardial dysfunction and mortality in the literature. miR-148a-3p is a novel repressor of IKBKB, NF-κB signaling and inflammation. In our study, 118 genes were associated with the 3 upregulated miRNAs and 601 genes were associated with the 3 downregulated miRNAs. GO enrichment analysis showed that upregulated miRNA associated genes were enriched in regulation of transcription and cell cycle. Downregulated miRNA associated genes were enriched in regulation of cell proliferation.   Conclusions:  A change in sodium intake affects miRNA expression, which could be one of the underlying mechanisms that high sodium intake promotes hypertension and CVD.
Equivalence? Clarifications Required—Reply
Authors: David H. Barlow, Matthew W. Gallagher, Todd J. Farchione
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications
Authors: M. Smalley, B. Shanthappa, H. Gertje, M. Lawson, B. Ulaganathan, A. Thayakumar, L. Maciejko, P. Radhakrishnan, M. Biswas, S. Thiyagarajan, B. Majumder, K. Gopinath, G. Babu, A. Goldman
Journal: Annals of Oncology (2017)
Deflazacort—New Costs of an Old Medicine
Authors: Stephen Mark Chrzanowski, Rosha Poudyal
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
SUV as a Possible Predictor of Disease Extent and Therapy Duration in Complex Tuberculosis
Authors: David Lang, Helmut Huber, Bernhard Kaiser, Irene Virgolini, Bernd Lamprecht, Michael Gabriel
Journal: Clinical Nuclear Medicine (2017)

Objective 18 F-FDG PET/CT provides information on disease extension and activity in neoplastic and inflammatory conditions. So far, little is known about whether SUVmax of a reference lesion can allow a prognosis to be given regarding patient-specific outcome parameters in complex cases of tuberculosis (TB). Methods We retrospectively identified 37 patients (21 men, 16 women; mean age, 50.4 years) who underwent 18 F-FDG PET/CT for the evaluation of active TB before treatment initiation. The aims were to examine whether the reference lesion SUVmax differed between patients with standard (≤9 months) and long-term (&gt;9 months) therapy and to define an SUVmax cutoff distinguishing those groups. In addition, we analyzed the prognostic value of SUVmax with regard to estimation of initial disease extent and lesion distribution pattern. Results Median therapy duration was 10 months (interquartile range, 3.25 months), and median SUVmax was 8 (interquartile range, 8.54). SUVmax was significantly ( P = 0.036) higher in patients treated longer than 9 months (10.1 vs 5.5). When applying a receiver operating characteristic curve analysis, an SUVmax cutoff value of 10 differentiated the standard and the long-term therapy group with a sensitivity of 50% and a specificity of 78.6% ( P = 0.087). Higher SUVmax corresponded with a larger number of affected organ systems ( P = 0.012 for ≤/&gt;1). Patients with extrathoracic involvement showed significantly higher SUVmax than did patients with limited intrathoracic disease ( P = 0.024) and received significantly longer antimycobacterial therapy ( P = 0.011). Conclusions Reference lesion SUVmax from pretherapy 18 F-FDG PET/CT may have prognostic properties in complicated cases of TB, especially regarding therapy duration and disease extent.
Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study
Authors: Kirsten M Williams, Jennifer Holter-Chakrabarty, Liza Lindenberg, Quyen Duong, Sara K Vesely, Chuong T Nguyen, Joseph P Havlicek, Karen Kurdziel, Juan Gea-Banacloche, Frank I Lin, Daniele N Avila, George Selby, Christopher G Kanakry, Shibo Li, Teresa Scordino, Stephen Adler, Catherine M Bollard, Peter Choyke, Ronald E Gress
Journal: The Lancet Haematology (2017)
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Authors: Hamid Bolouri, Jason E Farrar, Timothy Triche, Rhonda E Ries, Emilia L Lim, Todd A Alonzo, Yussanne Ma, Richard Moore, Andrew J Mungall, Marco A Marra, Jinghui Zhang, Xiaotu Ma, Yu Liu, Yanling Liu, Jaime M Guidry Auvil, Tanja M Davidsen, Patee Gesuwan, Leandro C Hermida, Bodour Salhia, Stephen Capone, Giridharan Ramsingh, Christian Michel Zwaan, Sanne Noort, Stephen R Piccolo, E Anders Kolb, Alan S Gamis, Malcolm A Smith, Daniela S Gerhard, Soheil Meshinchi
Journal: Nature Medicine (2017)
Short Leukocyte Telomere Length Precedes Clinical Expression of Atherosclerosis
Authors: Athanase Benetos, Simon Toupance, Sylvie Gautier, Carlos Labat, Masayuki Kimura, Pascal M. Rossi, Nicla Settembre, Jacques Hubert, Luc Frimat, Baptiste Bertrand, Mourad Boufi, Xavier Flecher, Nicolas Sadoul, Pascal Eschwege, Michèle Kessler, Irene P. Tzanetakou, Ilias P. Doulamis, Panagiotis Konstantopoulos, Aspasia Tzani, Marilina Korou, Anastasios Gkogkos, Konstantinos Perreas, Evangelos Menenakos, Georgios Samanidis, Michail Vasiloglou-Gkanis, Jeremy D. Kark, Serguei Malikov, Simon Verhulst, Abraham Aviv
Journal: Circulation Research (2017)

Short telomere length (TL) in leukocytes is associated with atherosclerotic cardiovascular disease (ASCVD). It is unknown whether this relationship stems from having inherently short leukocyte TL (LTL) at birth or a faster LTL attrition thereafter. LTL represents TL in the highly proliferative hematopoietic system, whereas TL in skeletal muscle represents a minimally replicative tissue.We measured LTL and muscle TL (MTL) in the same individuals with a view to obtain comparative metrics for lifelong LTL attrition and learn about the temporal association of LTL with ASCVD.Our Discovery Cohort comprised 259 individuals aged 63±14 years (mean±SD), undergoing surgery with (n=131) or without (n=128) clinical manifestation of ASCVD. In all subjects, MTL adjusted for muscle biopsy site (MTLA) was longer than LTL and the LTL-MTLA gap similarly widened with age in ASCVD patients and controls. Age- and sex-adjusted LTL (P=0.005), but not MTLA (P=0.90), was shorter in patients with ASCVD than controls. The TL gap between leukocytes and muscle (LTL-MTLA) was wider (P=0.0003), and the TL ratio between leukocytes and muscle (LTL/MTLA) was smaller (P=0.0001) in ASCVD than in controls. Findings were replicated in a cohort comprising 143 individuals.This first study to apply the blood-and-muscle TL model shows more pronounced LTL attrition in ASCVD patients than controls. The difference in LTL attrition was not associated with age during adulthood suggesting that increased attrition in early life is more likely to be a major explanation of the shorter LTL in ASCVD patients.URL: http://www.clinicaltrials.gov. Unique identifier: NCT02176941.
Defining adherence to therapeutic exercise for musculoskeletal pain: a systematic review
Authors: Daniel L Bailey, Melanie A Holden, Nadine E Foster, Jonathan G Quicke, Kirstie L Haywood, Annette Bishop
Journal: British Journal of Sports Medicine (2018)

Objective To establish the meaning of the term ‘adherence’ (including conceptual and measurement definitions) in the context of therapeutic exercise (TE) for musculoskeletal (MSK) pain. Design Systematic review using a search strategy including terms for: adherence, TE and MSK pain. Identified studies were independently screened for inclusion by two researchers. Two independent researchers extracted data on: study type; MSK pain population; type of TE used; definitions, parameters, measurement methods and values of adherence. Data sources Seven electronic databases were searched from inception to December 2016. Eligibility criteria Any study type featuring TE for adults with MSK pain and containing a definition of adherence, or a description of how adherence was measured. Results 459 studies were identified and 86 were included in the review. Most were prospective cohort studies and featured back and/or neck pain. Strengthening and stretching were the most common types of TE. A clearly identifiable definition of adherence was provided in 40% of the studies, with 12% using the same definition. Exercise frequency was the most commonly measured parameter of adherence, with self-report logs the most common measurement method. The most common value range used to determine satisfactory adherence was 80%–99% of the recommended exercise dose. Conclusion No single definition of adherence to TE was apparent. We found no definition of adherence that specifically related to TE for MSK pain or described the dimensions of TE that should be measured. We recommend conceptualising adherence to TE for MSK pain from the perspective of all relevant stakeholders.
Concerns About Conclusions of Self-monitoring of Blood Glucose
Authors: Augusto Pimazoni-Netto, David Rodbard
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study
Authors: Elena Nikiphorou, Désirée van der Heijde, Sam Norton, Robert BM Landewé, Anna Molto, Maxime Dougados, Filip E Van den Bosch, Sofia Ramiro
Journal: Annals of the Rheumatic Diseases (2017)

Objectives The value of biological disease-modifying antirheumatic drugs (bDMARDs) in spondyloarthritis (SpA) is well recognised, but global access to these treatments can be limited due to high costs and other factors. This study explores country variation in the use of bDMARDs in SpA in relation to country-level socioeconomic factors. Methods Patients fulfilling the Assessment in SpondyloArthritis International Society (ASAS) SpA criteria in the multinational, cross-sectional ASAS Comorbidities in Spondyloarthritis study were studied. Current use of bDMARDs or conventional synthetic DMARDs (csDMARDs) was investigated in separate models, with multilevel logistic regression analysis, taking the country level into account. Contribution of socioeconomic factors, including country health expenditures, gross domestic product and human development index as independent country-level factors, was explored individually, in models adjusted for sociodemographic as well as clinical variables. Results In total, 3370 patients from 22 countries were included (mean (SD) age 43 (14) years; 66% male; 88% axial disease). Across countries, 1275 (38%) patients were bDMARD users. Crude mean bDMARD use varied between 5% (China) to 74% (Belgium). After adjustment for relevant sociodemographic and clinical variables, important variation in bDMARD use across countries remained (P&lt;0.001). Country-level socioeconomic factors, specifically higher health expenditures, were related to higher bDMARD uptake, though not meeting statistical significance (OR 1.96; 95% CI 0.94 to 4.10). csDMARD uptake was significantly lower in countries with higher health expenditures (OR 0.32; 95% CI 0.15 to 0.65). Similar trends were seen with the other socioeconomic variables. Conclusions There remains important residual variation across countries in bDMARD uptake of patients with SpA followed in specialised SpA centres. This is independent of well-known factors for bDMARD use such as clinical and country-level socioeconomic factors.
Management of the Node-Positive Axilla in Breast Cancer in 2017
Authors: Monica Morrow
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal